Listed

CNO Financial Group, Inc.: Form 10-Q for the period ended Mar 31, 2024

Filed with the SEC on May 6, 2024 and accepted by EDGAR at May 6, 2024, 10:49 ET.

Share

Management's discussion and analysis

As filed, 90,781 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

In this section, we review the consolidated financial condition of CNO at March 31, 2024, and its consolidated results of operations for the three months ended March 31, 2024 and 2023, and, where appropriate, factors that may affect future financial performance. Please read this discussion in conjunction with the accompanying consolidated financial statements and notes. Results for interim periods are not necessarily indicative of the results that may be expected for a full year.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Our statements, trend analyses and other information contained in this report and elsewhere (such as in filings by CNO with the SEC, press releases, presentations by CNO or its management or oral statements) relative to markets for CNO's products and trends in CNO's operations or financial results, as well as other statements, contain forward-looking statements within the meaning of the federal securities laws and the Private Securities Litigation Reform Act of 1995. Forward-looking statements typically are identified by the use of terms such as "anticipate," "believe," "plan," "estimate," "expect," "project," "intend," "may," "will," "would," "contemplate," "possible," "attempt," "seek," "should," "could," "goal," "target," "on track," "comfortable with," "optimistic," "guidance," "outlook," "sustainable" and similar words, although some forward-looking statements are expressed differently. You should consider statements that contain these words carefully because they describe our expectations, plans, strategies and goals and our beliefs concerning future business conditions, our results of operations, financial position, and our business outlook or they state other "forward-looking" information based on currently available information. The "Risk Factors" section of our 2023 Annual Report on Form 10-K provides examples of risks, uncertainties and events that could cause our actual results to differ materially from the expectations expressed in our forward-looking statements. Assumptions and other important factors that could cause our actual results to differ materially from those anticipated in our forward-looking statements include, among other things:

  • general economic, market and political conditions and uncertainties, including the performance and fluctuations of the financial markets which may affect the value of our investments as well as our ability to raise capital or refinance existing indebtedness and the cost of doing so;
  • the impact of pandemics, including the novel coronavirus pandemic, and major public health issues and the resulting financial market, economic and other impacts;
  • exposure to interest rate risk, including interest rate volatility, may negatively impact our results of operations, financial position or cash flow;
  • future investment results, including the impact of realized losses (including other-than-temporary impairment charges) may diminish the value of our invested assets and negatively impact our profitability, our financial condition and our liquidity;
  • the ultimate outcome of lawsuits filed against us and other legal and regulatory proceedings to which we are subject;
  • our ability to make anticipated changes to certain non-guaranteed elements of our life insurance products;
  • our ability to obtain adequate and timely rate increases on our health products, including our long-term care business;
  • the receipt of any required regulatory approvals for dividend and surplus debenture interest payments from our insurance subsidiaries;
  • mortality, morbidity, the increased cost and usage of health care services, persistency, the adequacy of our previous reserve estimates, changes in the health care market and other factors which may affect the profitability of our insurance products;
  • the recoverability of our deferred tax assets and the effect of potential ownership changes and tax rate changes on their value;
  • our assumption that the positions we take on our tax return filings will not be successfully challenged by the Internal Revenue Service;
  • changes in accounting principles and the interpretation thereof;
  • our ability to continue to satisfy the financial ratio and balance requirements and other covenants of our debt agreements;
  • our ability to identify products and markets in which we can compete effectively against competitors with greater market share, higher ratings, greater financial resources and stronger brand recognition;
  • our ability to generate sufficient liquidity to meet our debt service obligations and other cash needs;
  • changes in capital deployment opportunities;
  • our ability to maintain effective controls over financial reporting and modeling;
  • our ability to continue to recruit and retain productive agents and distribution partners;
  • customer response to new products, distribution channels and marketing initiatives;
  • inflation or other unfavorable economic or business conditions may impact the sales and persistency of insurance products, a portion of our insurance policy benefits affected by increased medical coverage costs and various selling, general and administrative expenses;
  • our ability to maintain the financial strength ratings of CNO and our insurance company subsidiaries as well as the impact of our ratings on our business, our ability to access capital, and the cost of capital;
  • regulatory changes or actions, including: those relating to regulation of the financial affairs of our insurance companies, such as the calculation of risk-based capital and minimum capital requirements, and payment of dividends and surplus debenture interest to us; regulation of the sale, underwriting and pricing of products; health care regulation affecting health insurance products; and privacy laws and regulations;
  • changes in the Federal income tax laws and regulations which may affect or eliminate the relative tax advantages of some of our products or affect the value of our deferred tax assets;
  • availability and effectiveness of reinsurance arrangements, as well as the impact of any defaults or failure of reinsurers to perform;
  • the performance of third party service providers (both domestic and international) and potential difficulties arising from outsourcing arrangements;
  • expectations for the growth rate of sales, collected premiums, annuity deposits and assets;
  • interruption in telecommunication, information technology or other operational systems or failure to maintain the security, confidentiality or privacy of sensitive data on such systems;
  • events of terrorism, natural disasters or other catastrophic events, including potential adverse impacts from climate change which may increase the frequency or severity of weather-related disasters;
  • cyber-security attacks, risk of data loss and other security breaches;
  • ineffectiveness of risk management policies and procedures in identifying, monitoring and managing risks; and
  • the risk factors or uncertainties listed from time to time in our filings with the SEC.

Other factors and assumptions not identified above are also relevant to the forward-looking statements, and if they prove incorrect, could also cause actual results to differ materially from those projected.

All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by the foregoing cautionary statement. Our forward-looking statements speak only as of the date made. We assume no obligation to update or to publicly announce the results of any revisions to any of the forward-looking statements to reflect actual results, future events or developments, changes in assumptions or changes in other factors affecting the forward-looking statements.

The reporting of risk-based capital ("RBC") measures is not intended for the purpose of ranking any insurance company or for use in connection with any marketing, advertising or promotional activities.

OVERVIEW

We are a holding company for a group of insurance companies that develop, market and administer health insurance, annuity, individual life insurance and other insurance and financial services products. We focus on serving middle-income pre-retiree and retired Americans, which we believe are attractive, underserved, high growth markets. We sell our products through exclusive agents, independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing.

We view our operations as three insurance product lines (annuity, health and life) and the investment and fee income segments. Our segments are aligned based on their common characteristics, comparability of profit margins and the way management makes operating decisions and assesses the performance of the business.

Our insurance product line segments (annuity, health and life) include marketing, underwriting and administration of the policies our insurance subsidiaries sell. The business written in each of the three product categories through all of our insurance subsidiaries is aggregated allowing management and investors to assess the performance of each product category. When analyzing profitability of these segments, we use insurance product margin as the measure of profitability, which is: (i) insurance policy income; and (ii) net investment income allocated to the insurance product lines; less (i) insurance policy benefits and interest credited to policyholders; and (ii) amortization of deferred acquisition costs and present value of future profits, non-deferred commissions and advertising expense. Net investment income is allocated to the product lines using the book yield of investments backing the block of business, which is applied to the average insurance liabilities, net of insurance intangibles, for the block in each period. Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account balances for annuity products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsured business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities.

Income from insurance products is the sum of the insurance margins of the annuity, health and life product lines, less expenses allocated to the insurance lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes. Management believes insurance product margin and income from insurance products help provide a better understanding of the business and a more meaningful analysis of the results of our insurance product lines.

We market our products through the Consumer and Worksite Divisions that reflect the customers served by the Company. The Consumer and Worksite Divisions are primarily focused on marketing insurance products, several types of which are sold in both divisions and underwritten in the same manner.

The Consumer Division serves individual consumers, engaging with them on the phone, virtually, online, face-to-face with agents, or through a combination of sales channels. This structure unifies consumer capabilities into a single division and integrates the strength of our agent sales forces with one of the largest direct-to-consumer insurance businesses with proven experience in advertising, web/digital and call center support.

The Worksite Division focuses on the sale of voluntary benefit life and health insurance products in the workplace for businesses, associations, and other membership groups, interacting with customers at their place of employment and virtually.

With a separate Worksite Division, we are bringing a sharper focus to this high-growth business while further capitalizing on the strength of our wholly-owned subsidiary, Optavise, a national provider of year-round technology-driven employee benefits management services.

The investment segment involves the management of our capital resources, including investments and the management of corporate debt and liquidity. Our measure of profitability of this segment is the total net investment income not allocated to the insurance products. Investment income not allocated to product lines represents net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable, investment borrowings and financing arrangements; (iv) expenses related to the FABN program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders. Investment income not allocated to product lines includes investment income on investments in excess of amounts allocated to product lines, investments held by our holding companies, the spread we earn from our FHLB investment borrowing and FABN programs and variable components of investment income (including call and prepayment income, adjustments to returns on structured securities due to cash flow changes, income (loss) from COLI and alternative investment income not allocated to product lines), net of interest expense on corporate debt and financing arrangements. The spread earned from our FHLB investment borrowing and FABN programs includes the investment income on the matched assets less: (i) interest on investment borrowings related to the FHLB investment borrowing program; (ii) interest credited on funding agreements; and (iii) amortization of deferred acquisition costs related to the FABN program.

Our fee income segment includes the earnings generated from sales of third-party insurance products, services provided by Optavise and the operations of our broker/dealer and registered investment advisor.

Expenses not allocated to product lines include the expenses of our corporate operations, excluding interest expense on debt.

The following summarizes our earnings for the three months ending March 31, 2024 and 2023 (dollars in millions, except per share data):

Insurance product margin Three months ended March 31, 2024 2023
Annuity margin $52.0 $57.3
Health margin 123.0 116.5
Life margin 54.6 47.4
Total insurance product margin 229.6 221.2
Allocated expenses (161.6) (157.5)
Income from insurance products 68.0 63.7
Fee income 11.3 15.5
Investment income not allocated to product lines 12.3 15.5
Expenses not allocated to product lines (16.8) (18.3)
Operating earnings before taxes 74.8 76.4
Income tax expense on operating income (17.3) (17.8)
Net operating income (a) 57.5 58.6
Net realized investment losses from sales and change in allowance for credit losses (4.6) (12.7)
Net change in market value of investments recognized in earnings 12.4 (1.9)
Changes in fair value of embedded derivative liabilities and market risk benefits 64.0 (65.1)
Other (.4) 2.3
Net non-operating income (loss) before taxes 71.4 (77.4)
Income tax (expense) benefit on non-operating income (loss) (16.6) 18.0
Net non-operating income (loss) 54.8 (59.4)
Net income (loss) $112.3 $(.8)
Per diluted share
Net operating income $.52 $.51
Net non-operating income (loss) .49 (.52)
Net income (loss) $1.01 $(.01)

69

(a) Management believes that an analysis of net income applicable to common stock before: (i) net realized investment gains or losses from sales, impairments and change in allowance for credit losses, net of taxes; (ii) net change in market value of investments recognized in earnings, net of taxes; (iii) changes in fair value of embedded derivative liabilities and MRBs related to our fixed indexed annuities, net of taxes; (iv) fair value changes related to the agent deferred compensation plan, net of taxes; (v) loss related to reinsurance transactions, net of taxes; (vi) loss on extinguishment of debt, net of taxes; (vii) changes in the valuation allowance for deferred tax assets and other tax items; and (viii) other non-operating items consisting primarily of earnings attributable to VIEs, net of taxes ("net operating income," a non-GAAP financial measure) is important to evaluate the financial performance of the company, and is a key measure commonly used in the life insurance industry. The income tax expense or benefit allocated to the items included in net non-operating income (loss) represents the current and deferred income tax expense or benefit allocated to the items included in non-operating earnings. Management uses this measure to evaluate performance because the items excluded from net operating income can be affected by events that are unrelated to the Company's underlying fundamentals. The table above reconciles the non-GAAP measure to the corresponding GAAP measure.

In addition, management uses these non-GAAP financial measures in its budgeting process, financial analysis of segment performance and in assessing the allocation of resources. We believe these non-GAAP financial measures enhance an investor's understanding of our financial performance and allows them to make more informed judgments about the Company as a whole. These measures also highlight operating trends that might not otherwise be apparent. However, net operating income is not a measurement of financial performance under GAAP and should not be considered as an alternative to cash flow from operating activities, as measures of liquidity, or as an alternative to net income as measures of our operating performance or any other measures of performance derived in accordance with GAAP. In addition, net operating income should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. Net operating income has limitations as an analytical tool, and you should not consider such measure either in isolation or as a substitute for analyzing our results as reported under GAAP. Our definition and calculation of net operating income are not necessarily comparable to other similarly titled measures used by other companies due to different methods of calculation. Also, as we adopted the new accounting standard related to targeted improvements to the accounting for long-duration insurance contracts effective January 1, 2023, we updated our method of determining non-operating earnings for our fixed indexed annuities to better identify the volatile non-economic impacts of that line of business. This resulted in fixed indexed annuity margins that more closely reflect the economics of the business.

GOVERNMENTAL REGULATION

In 2023, the U.S. Department of Labor (the "DOL") proposed a regulation to change the definition of "fiduciary" for purposes of the Employee Retirement Income Security Act of 1974 ("ERISA") and parallel provisions of the Code, when a financial professional, including an insurance producer, provides investment advice, and to amend various existing prohibited transaction exemptions ("PTEs") that financial professionals rely on when making recommendations. On April 23, 2024, the DOL finalized and published this new definition of "fiduciary" for purposes of ERISA and parallel provisions of the Code and finalized and published amendments to these PTEs. We do not expect these developments to have a significant impact on our business.

CRITICAL ACCOUNTING ESTIMATES

Refer to "Critical Accounting Policies" in our 2023 Annual Report on Form 10-K for information on our other accounting policies that we consider critical in preparing our consolidated financial statements.

RESULTS OF OPERATIONS

The following tables and narratives summarize the operating results of our segments (dollars in millions):

Insurance product margin Annuity: Three months ended March 31, 2024 2023
Insurance policy income $7.3 $5.1
Net investment income 134.5 125.4
Insurance policy benefits (11.3) (8.7)
Interest credited (58.3) (48.1)
Amortization and non-deferred commissions (a) (20.2) (16.4)
Annuity margin 52.0 57.3
Health:
Insurance policy income 398.4 401.4
Net investment income 74.3 74.0
Insurance policy benefits (308.5) (318.1)
Amortization and non-deferred commissions (a) (41.2) (40.8)
Health margin 123.0 116.5
Life:
Insurance policy income 222.7 219.0
Net investment income 36.5 36.3
Insurance policy benefits (144.0) (147.2)
Interest credited (12.5) (12.1)
Amortization and non-deferred commissions (a) (23.5) (19.9)
Advertising expense (24.6) (28.7)
Life margin 54.6 47.4
Total insurance product margin 229.6 221.2
Allocated expenses:
Branch office expenses (19.8) (19.8)
Other allocated expenses (141.8) (137.7)
Income from insurance products 68.0 63.7
Fee income 11.3 15.5
Investment income not allocated to product lines 12.3 15.5
Expenses not allocated to product lines (16.8) (18.3)
Operating earnings before taxes 74.8 76.4
Income tax expense on operating income (17.3) (17.8)
Net operating income $57.5 $58.6

(a) Amortization and non-deferred commissions are comprised of: (i) the amortization of deferred acquisition costs and present value of future profits; and (ii) commission expenses that are not directly related to the successful acquisition of new or renewal insurance contracts and, therefore, are not eligible to be deferred. Such non-deferred commissions are included in other operating costs and expenses on the consolidated statement of operations.

CNO is the top tier holding company for a group of insurance companies that develop, market and administer health insurance, annuity, individual life insurance and other insurance and financial services products. We view our operations by segments, which consist of insurance product lines. These products are distributed by our two divisions. The Consumer Division serves individual consumers, engaging with them on the phone, virtually, online, face-to-face with agents, or through a combination of sales channels. The Worksite Division focuses on the sale of voluntary benefit life and health insurance products in the workplace for businesses, associations, and other membership groups, interacting with customers at their place of employment and virtually.

Insurance product margin is management's measure of the profitability of its annuity, health and life product lines' performance and consists of insurance policy income plus allocated investment income less insurance policy benefits, interest credited, commissions, advertising expense and amortization of acquisition costs. Income from insurance products is the sum of the insurance margins of the annuity, health and life product lines, less expenses allocated to the insurance lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes. Management believes this information helps provide a better understanding of the business and a more meaningful analysis of the results of our insurance product lines.

Net investment income is allocated to the product lines using the book yield of investments backing the block of business, which is applied to the average insurance liabilities for the block in each period. Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account balances for annuity products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsured business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities. Investment income not allocated to product lines represents net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable, investment borrowings and financing arrangements; (iv) expenses related to the FABN program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders. Investment income not allocated to product lines includes investment income on investments in excess of amounts allocated to product lines, investments held by our holding companies, the spread we earn from our FHLB investment borrowing and FABN programs and variable components of investment income (including call and prepayment income, adjustments to returns on structured securities due to cash flow changes, income (loss) from COLI and alternative investment income not allocated to product lines), net of interest expense on corporate debt and financing arrangements. The spread earned from our FHLB investment borrowing and FABN programs includes the investment income on the matched assets less: (i) interest on investment borrowings related to the FHLB investment borrowing program; (ii) interest credited on funding agreements; and (iii) amortization of deferred acquisition costs related to the FABN program.

Summary of Operating Results: Net operating income was $57.5 million in the first quarter of 2024, compared to $58.6 million in the first quarter of 2023.

Insurance product margin was $229.6 million in the first quarter of 2024 compared to $221.2 million in the first quarter of 2023. Fluctuations by product line are discussed in greater detail in the narratives that follow.

Total net investment income (comprised of investment income allocated and not allocated to products) increased 2.5 percent to $257.6 million in the first quarter of 2024, as compared to $251.2 million in the first quarter of 2023, reflecting growth in the investment portfolio and higher yields. Such results reflected net unfavorable mark-to-market impacts of $24.3 million and $9.4 million in the first quarters of 2024 and 2023, respectively. The performance of our alternative investments is typically reported a quarter in arrears. The alternative results in the first quarter of 2024 were adversely impacted by mark-to-market impacts on certain real estate partnerships ("REPs") driven by the annual appraisals of the underlying real estate assets in the context of higher cap rates in the current higher interest rate environment. The book value of these REPs was $86 million at March 31, 2024. The underlying properties held by the REPs are occupied by investment grade tenants and have long-term non-cancellable leases. In addition, these REPs continue to produce stable cash flows at the property level and stable distributions to the Company.

Total allocated and unallocated expenses are summarized in the table below (dollars in millions):

Three months ended March 31, 2024 2023
Expenses allocated to product lines $161.6 $157.5
Expenses not allocated to product lines 16.8 18.3
Adjusted total $178.4 $175.8

Total allocated and unallocated expenses in the first three months of 2024 were up slightly as compared to the same period in the prior year, and were in line with our expectations. Our projected expense ratio guidance for the full year of 2024 is between 18.8 percent to 19.2 percent and remains unchanged. The expense ratio is defined as total allocated and unallocated expenses divided by the sum of insurance policy income and net investment income allocated to products.

The fee income segment is summarized below (dollars in millions):

Three months ended March 31, 2024 2023
Fee revenue $50.5 $51.3
Operating costs and expenses (39.2) (35.8)
Net fee income $11.3 $15.5

The decrease in net fee income in the first three months of 2024 is primarily due to: (i) changes to our revenue recognition assumptions related to sales of third party products by our Consumer Division reflecting less favorable policy persistency and higher agent persistency resulting in higher renewal commissions, as compared to the prior period; partially offset by (ii) higher sales of such third party products in the 2024 period as compared to the same period in the prior year.

Investment income not allocated to product lines generally fluctuates from period to period based on the level of prepayment income (including call premiums) and trading account income; the performance of our alternative investments (which are typically reported a quarter in arrears); the earnings related to the investments underlying our COLI; and the spread we earn from our FHLB investment borrowing and FABN programs.

The effective tax rate for the first three months of 2024 was 23.2 percent.

Margin from Annuity Products (dollars in millions):

Annuity margin: Fixed indexed annuities Three months ended March 31, 2024 2023
Insurance policy income $6.0 $3.6
Net investment income 108.4 98.8
Insurance policy benefits (5.8) (4.1)
Interest credited (46.7) (36.4)
Amortization and non-deferred commissions (18.5) (15.4)
Margin from fixed indexed annuities $43.4 $46.5
Average net insurance liabilities $9,636.3 $9,183.8
Margin/average net insurance liabilities 1.80% 2.03%
Fixed interest annuities
Insurance policy income $.1 $.3
Net investment income 20.6 20.9
Insurance policy benefits (.4) (.1)
Interest credited (11.1) (11.1)
Amortization and non-deferred commissions (1.6) (.9)
Margin from fixed interest annuities $7.6 $9.1
Average net insurance liabilities $1,588.0 $1,630.9
Margin/average net insurance liabilities 1.91% 2.23%
Other annuities
Insurance policy income $1.2 $1.2
Net investment income 5.5 5.7
Insurance policy benefits (5.1) (4.5)
Interest credited (.5) (.6)
Amortization and non-deferred commissions (.1) (.1)
Margin from other annuities $1.0 $1.7
Average net insurance liabilities $439.9 $469.5
Margin/average net insurance liabilities .91% 1.45%
Total annuity margin $52.0 $57.3
Average net insurance liabilities $11,664.2 $11,284.2
Margin/average net insurance liabilities 1.78% 2.03%

Margin from fixed indexed annuities was $43.4 million in the first quarter of 2024 compared to $46.5 million in the first quarter of 2023. The decrease in margin in the 2024 period is primarily due to: (i) additional amortization and unfavorable reserve impacts from higher policy surrender activity; (ii) slight spread compression driven by increased surrenders of higher spread products; partially offset by (iii) growth in the block and higher yields. Average net insurance liabilities (policyholder account balances less: (i) amounts related to reinsured business; (ii) deferred acquisition costs; (iii) present value of future profits; and (iv) the value of unexpired options credited to insurance liabilities) were $9,636.3 million and $9,183.8 million in the first quarters of 2024 and 2023, respectively, driven by deposits and reinvested returns in excess of withdrawals. The increase in net insurance liabilities results in higher net investment income allocated. The earned yield was 4.50 percent in the first quarter of 2024 up from 4.30 percent in the first quarter of 2023, reflecting higher portfolio yields.

Net investment income and interest credited exclude the change in market values of the underlying options supporting the fixed indexed annuity products and corresponding offsetting amount credited to policyholder account balances. Such amounts were $128.6 million and $16.5 million in the first quarters of 2024 and 2023, respectively.

Margin from fixed interest annuities was $7.6 million in the first quarter of 2024 compared to $9.1 million in the first quarter of 2023, driven primarily by additional amortization from higher policy surrenders and a reduction in the size of the block. Average net insurance liabilities were $1,588.0 million in the first quarter of 2024 compared to $1,630.9 million in the first quarter of 2023, driven by withdrawals in excess of deposits and reinvested returns. The decrease in net insurance liabilities resulted in lower net investment income allocated, however, the earned yield increased to 5.19 percent in the first quarter of 2024 from 5.13 percent in the first quarter of 2023, reflecting higher portfolio yields.

Margin from other annuities was $1.0 million in the first quarter of 2024 compared to $1.7 million in the first quarter of 2023. The margin on this relatively small block of business is sensitive to annuitant mortality related to contracts with life contingencies. An increase in mortality in this block will result in a decrease in insurance liabilities and insurance policy benefits. Such mortality was lower in the 2024 period compared to the same period in 2023.

Margin from Health Products (dollars in millions):

Health margin: Supplemental health Three months ended March 31, 2024 2023
Insurance policy income $179.7 $179.0
Net investment income 39.0 38.6
Insurance policy benefits (125.8) (128.2)
Amortization and non-deferred commissions (27.5) (26.1)
Margin from supplemental health $65.4 $63.3
Margin/insurance policy income 36% 35%
Medicare supplement
Insurance policy income $151.7 $156.5
Net investment income 1.4 1.3
Insurance policy benefits (116.4) (120.5)
Amortization and non-deferred commissions (10.2) (11.2)
Margin from Medicare supplement $26.5 $26.1
Margin/insurance policy income 17% 17%
Long-term care
Insurance policy income $67.0 $65.9
Net investment income 33.9 34.1
Insurance policy benefits (66.3) (69.4)
Amortization and non-deferred commissions (3.5) (3.5)
Margin from long-term care $31.1 $27.1
Margin/insurance policy income 46% 41%
Total health margin $123.0 $116.5
Margin/insurance policy income 31% 29%

Margin from supplemental health business was $65.4 million in the first quarter of 2024 compared to $63.3 million in the first quarter of 2023, reflecting growth in the block. The margin as a percentage of insurance policy income was 36 percent in the first quarter of 2024 compared to 35 percent in the prior year period.

Our supplemental health products (including specified disease, accident and hospital indemnity products) generally provide fixed or limited benefits. For example, payments under cancer insurance policies are generally made directly to, or at the direction of, the policyholder following diagnosis of, or treatment for, a covered type of cancer. Approximately three-fourths of our supplemental health policies inforce (based on policy count) are sold with return of premium or cash value riders. The return of premium rider generally provides that after a policy has been inforce for a specified number of years or upon the policyholder reaching a specified age, we will pay to the policyholder, or a beneficiary under the policy, the aggregate amount of all premiums paid under the policy, without interest, less the aggregate amount of all claims incurred under the policy. The cash value rider is similar to the return of premium rider, but also provides for payment of a graded portion of the return of premium benefit if the policy terminates before the return of premium benefit is earned. Accordingly, the net cash flows from these products generally result in the accumulation of amounts in the early years of a policy (reflected in our earnings as reserve increases which is a component of insurance policy benefits) which will be paid out as benefits in later policy years (reflected in our earnings as reserve decreases which offset the recording of benefit payments). As the policies age, insurance policy benefits will typically increase, but the increase in benefits will be partially offset by investment income earned on the accumulated assets.

Margin from Medicare supplement business was $26.5 million and $26.1 million in the first quarters of 2024 and 2023, respectively. The increase in margin on the Medicare supplement business is primarily due to favorable claims experience in the 2024 period, as compared to the 2023 period, partially offset by a reduction in the size of the block. Claim experience will fluctuate from period to period. Insurance policy income was $151.7 million in the first quarter of 2024, down 3.1 percent from the first quarter of 2023, reflecting lower sales in recent periods partially offset by premium rate increases. Over the last several years, we have experienced a shift in the sale of Medicare supplement policies to the sale of Medicare Advantage policies. We receive fee income when Medicare Advantage policies of other providers are sold, which is recorded in our Fee income segment. We continue to invest in both our Medicare supplement products and Medicare Advantage distribution to meet our customers' needs and preferences.

Medicare supplement business consists of both individual and group policies. Government regulations generally require we attain and maintain a ratio of total benefits incurred to total premiums earned (excluding changes in policy benefits reserves which is a component of Insurance policy benefits) of not less than 65 percent on individual products and not less than 75 percent on group products. The ratio is determined after three years from the original issuance of the policy and over the lifetime of the policy and measured in accordance with statutory accounting principles. Since the insurance product liabilities we establish for Medicare supplement business are subject to significant estimates, the ultimate claim liability we incur for a particular period is likely to be different than our initial estimate. Changes to our estimates are reflected in insurance policy benefits in the period the change is determined.

Margin from Long-term care products was $31.1 million and $27.1 million in the first quarters of 2024 and 2023, respectively. The margin as a percentage of insurance policy income was 46 percent in the first quarter of 2024 compared to 41 percent in the first quarter of 2023. The increase in margin in the 2024 period is primarily due to growth in the block and lower insurance policy benefits, as compared to the 2023 period. Claim experience will fluctuate from quarter to quarter.

Margin from Life Products (dollars in millions):

Life margin: Interest-sensitive life Three months ended March 31, 2024 2023
Insurance policy income $46.6 $44.5
Net investment income 13.2 13.1
Insurance policy benefits (19.9) (18.2)
Interest credited (12.3) (12.0)
Amortization and non-deferred commissions (5.1) (4.6)
Margin from interest-sensitive life $22.5 $22.8
Average net insurance liabilities $1,056.1 $1,032.0
Interest margin $.9 $1.1
Interest margin/average net insurance liabilities .34% .43%
Underwriting margin $21.6 $21.7
Underwriting margin/insurance policy income 46% 49%
Traditional life
Insurance policy income $176.1 $174.5
Net investment income 23.3 23.2
Insurance policy benefits (124.1) (129.0)
Interest credited (.2) (.1)
Amortization and non-deferred commissions (18.4) (15.3)
Advertising expense (24.6) (28.7)
Margin from traditional life $32.1 $24.6
Margin/insurance policy income 18% 14%
Margin excluding advertising expense/insurance policy income 32% 31%
Total life margin $54.6 $47.4

Margin from interest-sensitive life business was $22.5 million in the first quarter of 2024, down slightly from the first quarter of 2023, reflecting unfavorable claims experience, as compared to the 2023 period; partially offset by growth in the block due to sales in recent periods.

The interest margin was $0.9 million and $1.1 million in the first quarters of 2024 and 2023, respectively. Net investment income in the 2024 period was comparable to the 2023 period. The increase in average net insurance liabilities results in higher net investment income allocated, which is largely offset by lower earned yields. The earned yield was 5.00 percent and 5.08 percent in the first quarters of 2024 and 2023, respectively. The decrease in earned yields is due to the maturity or sale of higher yielding investments. Interest credited to policyholders may be changed annually but is subject to minimum guaranteed rates and, as a result, any reduction in our earned rate may not be fully reflected in the rate credited to policyholders.

Net investment income and interest credited exclude the change in market values of the underlying options supporting the fixed indexed life products and corresponding offsetting amount credited to policyholder account balances. Such amounts were $11.1 million and $2.1 million in the first quarters of 2024 and 2023, respectively.

Margin from traditional life business was $32.1 million and $24.6 million in the first quarters of 2024 and 2023, respectively. The increase in margin in the 2024 period, as compared to the same period in 2023, reflects growth in the block and lower insurance policy benefits and advertising expense.

Net investment income in the 2024 period was comparable to the 2023 period. The increase in average net insurance liabilities results in higher net investment income allocated, which is largely offset by lower earned yields. The earned yield was 4.67 percent and 4.70 percent in the first quarters of 2024 and 2023, respectively.

Advertising expense was $24.6 million in the first quarter of 2024, down 14 percent from the comparable period in 2023. The demand and cost of television advertising can fluctuate from period to period. We are disciplined with our marketing expenditures and will increase or decrease our marketing spend depending on the current economics of the purchase or other factors.

Collected Premiums From Annuity and Interest-Sensitive Life Products (dollars in millions):

Collected premiums from annuity and interest-sensitive life products: Three months ended March 31, 2024 2023
Annuities $393.3 $370.9
Interest-sensitive life 60.5 58.2
Total collected premiums from annuity and interest-sensitive life products $453.8 $429.1

Collected premiums from annuity and interest-sensitive products increased 5.8 percent in the first quarter of 2024 compared to the first quarter of 2023, primarily due to higher premium collections from fixed indexed annuity products.

Investment Income Not Allocated to Product Lines (dollars in millions):

Three months ended March 31, 2024 2023
Net investment income $469.2 $343.0
Allocated to product lines:
Annuity (134.5) (125.4)
Health (74.3) (74.0)
Life (36.5) (36.3)
Equity returns credited to policyholder account balances (139.7) (18.6)
Amounts allocated to product lines and credited to policyholder account balances (385.0) (254.3)
Impact of annual option forfeitures related to fixed indexed annuity surrenders 6.2 —
Amount related to variable interest entities and other non-operating items (12.6) (20.9)
Interest expense on debt (15.7) (15.7)
Interest expense on financing arrangements (1.2) —
Interest expense on investment borrowings from FHLB (31.4) (21.7)
Expenses related to FABN program (7.6) (7.6)
Less amounts credited to deferred compensation plans (offsetting investment income) (9.6) (7.3)
Total adjustments (71.9) (73.2)
Investment income not allocated to product lines $12.3 $15.5

The above table reconciles net investment income to investment income not allocated to product lines. Such amount will generally fluctuate from period to period based on the level of prepayment income (including call premiums) and trading account income; the performance of our alternative investments (which are typically reported a quarter in arrears); the earnings related to the investments underlying our COLI; and the spread we earn from our FHLB investment borrowing and FABN programs.

Net Non-Operating Income (Loss):

The following summarizes our net non-operating income (loss) for the three months ending March 31, 2024 and 2023 (dollars in millions):

Three months ended March 31, 2024 2023
Net realized investment losses from sales and change in allowance for credit losses $(4.6) $(12.7)
Net change in market value of investments recognized in earnings 12.4 (1.9)
Changes in fair value of embedded derivative liabilities and market risk benefits 64.0 (65.1)
Other (.4) 2.3
Net non-operating income (loss) before taxes $71.4 $(77.4)

80

Net realized investment losses in the three months ended March 31, 2024, were $4.6 million, net of a reduction in the allowance for credit losses of $1.5 million. Net realized investment losses in the three months ended March 31, 2023, were $12.7 million, including an increase in the allowance for credit losses of $1.5 million.

The change in market value of investments recognized in earnings was an increase (decrease) of $12.4 million and $(1.9) million in the first quarters of 2024 and 2023, respectively. The change in value will fluctuate from period to period based on market conditions.

We recognized an increase (decrease) in earnings of $64.0 million and $(65.1) million in the first three months of 2024 and 2023, respectively, resulting from changes in the fair value of embedded derivative liabilities and MRBs related to our fixed indexed annuities. Such amounts include the impacts of changes in market interest rates and equity impacts used to determine the estimated fair values of the embedded derivatives and MRBs.

Other non-operating items primarily include earnings attributable to VIEs that we are required to consolidate, net of affiliated amounts. Such earnings are not indicative of, and are unrelated to, the Company's underlying fundamentals.

LIQUIDITY AND CAPITAL RESOURCES

2024 Outlook

We are maintaining our previously disclosed guidance ranges as further discussed below.

We expect operating earnings per diluted share to be in the range of $3.10 to $3.30, excluding any significant items in the year. Given the lower returns on our alternative investments in the first quarter of 2024, we expect the full year operating earnings per share to be near the lower end of the range while also assuming that the returns on such alternative investments are more in line with our long term run-rate assumption for the balance of the year.

We continue to expect fee income to be slightly lower in 2024, as compared to 2023, with a slight change to the seasonal recognition of earnings with approximately one-third of such earnings recognized in the first quarter of 2024 (as compared to our previous expectation of 25 percent) and the remainder of such earnings generally recognized in the fourth quarter of 2024.

Our projected expense ratio guidance for the full year of between 18.8 percent to 19.2 percent for 2024 remains unchanged.

We continue to expect excess cash flow to the holding company to be in the range of $140 million to $200 million. The high end of the range assumes that we maintain our current pace of organic growth; maintain the current asset mix in our investment portfolio; and there is no significant change to economic conditions and the related pattern of credit migration in our investment portfolio. However, if we continue to accelerate organic growth; decide to accept a higher level of risk in our investment portfolio; and/or economic conditions deteriorate, prompting adverse credit migration, then additional capital would be required and excess cash flow would be toward the lower end of the range.

We expect to continue to manage to: (i) a consolidated RBC ratio of 375 percent for our U.S. based insurance subsidiaries; (ii) minimum holding company liquidity of $150 million; and (iii) a target debt to total capital, excluding accumulated other comprehensive income (loss), in the range of 25 percent to 28 percent.

Our capital structure as of March 31, 2024 and December 31, 2023 was as follows (dollars in millions):

Total capital: March 31, 2024 December 31, 2023
Corporate notes payable $1,141.0 $1,140.5
Shareholders’ equity:
Common stock 1.1 1.1
Additional paid-in capital 1,851.2 1,891.5
Accumulated other comprehensive loss (1,480.3) (1,576.8)
Retained earnings 1,995.7 1,899.8
Total shareholders’ equity 2,367.7 2,215.6
Total capital $3,508.7 $3,356.1

The following table summarizes certain financial ratios as of and for the three months ended March 31, 2024 and as of and for the year ended December 31, 2023:

March 31, 2024 December 31, 2023
Book value per common share $21.81 $20.26
Book value per common share, excluding accumulated other comprehensive income (loss) (a) 35.44 34.68
Debt to total capital ratios:
Corporate debt to total capital 32.5% 34.0%
Corporate debt to total capital, excluding accumulated other comprehensive income (loss) (a) 22.9% 23.1%

(a) This non-GAAP measure differs from the corresponding GAAP measure presented immediately above, because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in accumulated other comprehensive income (loss). Such volatility is often caused by changes in the estimated fair value of our investment portfolio resulting from changes in general market interest rates rather than the business decisions made by management. However, this measure does not replace the corresponding GAAP measure.

Liquidity for Insurance Operations

Our insurance companies generally receive adequate cash flows from premium collections and investment income to meet their obligations. Life insurance, long-term care and supplemental health insurance and annuity liabilities are generally long-term in nature. Life and annuity policyholders may, however, withdraw funds or surrender their policies, subject to any applicable penalty provisions; there are generally no withdrawal or surrender benefits for long-term care insurance. We actively manage the relationship between the duration of our invested assets and the estimated duration of benefit payments arising from contract liabilities.

Three of the Company's insurance subsidiaries (Bankers Life, Washington National and Colonial Penn) are members of the FHLB. As members of the FHLB, our insurance subsidiaries have the ability to borrow on a collateralized basis from the FHLB. We are required to hold certain minimum amounts of FHLB common stock as a condition of membership in the FHLB, and additional amounts based on the amount of the borrowings. At March 31, 2024, the carrying value of the FHLB common stock was $94.6 million. As of March 31, 2024, collateralized borrowings from the FHLB totaled $2.2 billion and the proceeds were used to purchase matched variable rate fixed maturity securities. The borrowings are classified as investment borrowings in the accompanying consolidated balance sheet. The borrowings are collateralized by investments with an estimated fair value of $2.7 billion at March 31, 2024, which are maintained in custodial accounts for the benefit of the FHLB.

State laws generally give state insurance regulatory agencies broad authority to protect policyholders in their jurisdictions. Regulators have used this authority in the past to restrict the ability of our insurance subsidiaries to pay any dividends or other amounts without prior approval. We cannot be assured that the regulators will not seek to assert greater supervision and control over our insurance subsidiaries' businesses and financial affairs.

Our estimated consolidated statutory RBC ratio of our U.S. based insurance subsidiaries was 391 percent at March 31, 2024, compared to 402 percent at December 31, 2023. In the first three months of 2024, the RBC ratio reflected: (i) an estimated consolidated statutory operating loss of $4 million; and (ii) insurance company dividends (net of capital contributions) of $43.3 million that were paid to the holding company. Our RBC ratio at March 31, 2024, exceeded our targeted RBC ratio of 375 percent and the minimum 350 percent that is reflected in our risk appetite statement that we share and discuss with rating agencies and insurance regulators. We believe that the 375 percent RBC ratio target continues to adequately support our financial strength and credit ratings.

Our insurance subsidiaries transfer exposure to certain risk to others through reinsurance arrangements. When we obtain reinsurance, we are still liable for those transferred risks in the event the reinsurer defaults on its obligations. The failure, insolvency, inability or unwillingness of one or more of the Company's reinsurers to perform in accordance with the terms of its reinsurance agreement could negatively impact our earnings or financial position and our consolidated statutory RBC ratio.

Financial Strength Ratings of our Insurance Subsidiaries

Financial strength ratings provided by S&P, AM Best Company ("AM Best"), Fitch Ratings ("Fitch") and Moody's Investor Services, Inc. ("Moody's") are the rating agency's opinions of the ability of our insurance subsidiaries to pay policyholder claims and obligations when due.

On March 18, 2024, S&P affirmed its "A-" financial strength ratings of our primary insurance subsidiaries and the outlook for these ratings is stable. S&P financial strength ratings range from "AAA" to "R" and some companies are not rated. An insurer rated "A", in S&P's opinion, has strong financial security characteristics, but is somewhat more likely to be affected by adverse business conditions than are insurers with higher ratings. Pluses and minuses show the relative standing within a category. S&P has twenty-one possible ratings. There are six ratings above the "A-" rating of our primary insurance subsidiaries and fourteen ratings that are below that rating.

On February 15, 2024, AM Best affirmed its "A" financial strength ratings of our primary insurance subsidiaries and the outlook for these ratings is stable. The "A" rating is assigned to companies that have an excellent ability, in AM Best's opinion, to meet their ongoing obligations to policyholders. AM Best ratings for the industry currently range from "A++ (Superior)" to "F (In Liquidation)" and some companies are not rated. AM Best has sixteen possible ratings. There are two ratings above the "A" rating of our primary insurance subsidiaries and thirteen ratings that are below that rating.

On November 15, 2023, Fitch upgraded the financial strength ratings of our primary insurance subsidiaries to "A" from "A-" and the outlook for these ratings is stable. An insurer rated "A", in Fitch's opinion, indicates a low expectation of ceased or interrupted payments and indicates strong capacity to meet policyholder and contract obligations. This capacity may, nonetheless, be more vulnerable to changes in circumstances or in economic conditions than is the case for higher ratings. Fitch ratings for the industry range from "AAA Exceptionally Strong" to "C Distressed" and some companies are not rated. Pluses and minuses show the relative standing within a category. Fitch has nineteen possible ratings. There are five ratings above the "A" rating of our primary insurance subsidiaries and thirteen ratings that are below that rating.

Moody's most recently reviewed its "A3" financial strength ratings of our primary insurance subsidiaries on May 12, 2023. The outlook for these ratings remains stable. Moody’s financial strength ratings range from "Aaa" to "C". These ratings may be supplemented with numbers "1", "2", or "3" to show relative standing within a category. In Moody's view, an insurer rated "A" offers good financial security, however, certain elements may be present which suggests a susceptibility to impairment sometime in the future. Moody's has twenty-one possible ratings. There are six ratings above the "A3" rating of our primary insurance subsidiaries and fourteen ratings that are below that rating.

Rating agencies have increased the frequency and scope of their credit reviews and requested additional information from the companies that they rate, including us. They may also adjust upward the capital and other requirements employed in their rating models for maintenance of certain ratings levels. We cannot predict what actions rating agencies may take, or what actions we may take in response. Accordingly, downgrades and outlook revisions related to us or the life insurance industry may occur in the future at any time and without notice by any rating agency. These could increase policy surrenders and withdrawals, adversely affect relationships with our distribution channels, reduce new sales, reduce our ability to borrow and increase our future borrowing costs.

Liquidity of the Holding Companies

Availability and Sources and Uses of Holding Company Liquidity; Limitations on Ability of Insurance Subsidiaries to Make Dividend and Surplus Debenture Interest Payments to the Holding Companies; Limitations on Holding Company Activities

At March 31, 2024, CNO, CDOC, Inc. ("CDOC", our wholly owned subsidiary and the immediate parent of Washington National and Conseco Life Insurance Company of Texas ("CLTX")) and our other non-insurance subsidiaries held $222.8 million of unrestricted cash and cash equivalents which was above our minimum target level of $150 million.

CNO and CDOC are holding companies with no business operations of their own; they depend on their operating subsidiaries for cash to make principal and interest payments on debt, and to pay administrative expenses and income taxes. CNO and CDOC receive cash from insurance subsidiaries, consisting of dividends and distributions, interest payments on surplus debentures and tax-sharing payments, as well as cash from non-insurance subsidiaries consisting of dividends, distributions, loans and advances. The principal non-insurance subsidiaries that provide cash to CNO and CDOC are 40|86 Advisors, Inc., which receives fees from the insurance subsidiaries for investment services, and CNO Services, LLC which receives fees from the insurance subsidiaries for providing administrative services. The agreements between our insurance subsidiaries and CNO Services, LLC and 40|86 Advisors, Inc., respectively, were previously approved by the domestic insurance regulator for each insurance company, and any payments thereunder do not require further regulatory approval.

The ability of our U.S. based insurance subsidiaries to pay dividends is subject to state insurance department regulations and is based on the financial statements of our insurance subsidiaries prepared in accordance with statutory accounting practices prescribed or permitted by regulatory authorities, which differ from GAAP. These regulations generally permit dividends to be paid from statutory earned surplus of the insurance company without regulatory approval for any 12-month period in amounts equal to the greater of (or in some states, the lesser of): (i) statutory net gain from operations or net income for the prior year; or (ii) 10 percent of statutory capital and surplus as of the end of the preceding year. However, as each of the immediate U.S. based insurance subsidiaries of CDOC has significant negative earned surplus, any dividend payments from the insurance subsidiaries require the prior approval of the director or commissioner of the applicable state insurance department. In the first three months of 2024, our U.S. based insurance subsidiaries paid dividends to CDOC totaling $68.0 million. We expect to receive regulatory approval for future dividends from our subsidiaries, but there can be no assurance that such payments will be approved or that the financial condition of our insurance subsidiaries will not change, making future approvals less likely.

CDOC holds surplus debentures from CLTX with an aggregate principal amount of $749.6 million. Interest payments on those surplus debentures do not require additional approval provided the RBC ratio of CLTX exceeds 100 percent (but do require prior written notice to the Texas Department of Insurance). The estimated RBC ratio of CLTX was 338 percent at March 31, 2024. CDOC also holds a surplus debenture from Colonial Penn with a principal balance of $160.0 million. Interest payments on that surplus debenture require prior approval by the Pennsylvania Insurance Department. Dividends and other payments from our non-insurance subsidiaries, including 40|86 Advisors, Inc. and CNO Services, LLC, to CNO or CDOC do not require approval by any regulatory authority or other third party. However, insurance regulators may prohibit payments by our insurance subsidiaries to parent companies if they determine that such payments could be adverse to our policyholders or contractholders.

The insurance subsidiaries of CDOC receive funds to pay dividends primarily from: (i) the earnings of their direct businesses; (ii) tax sharing payments received from subsidiaries (if applicable); and (iii) with respect to CLTX, dividends received from subsidiaries. At March 31, 2024, the subsidiaries of CLTX had earned surplus (deficit) as summarized below (dollars in millions):

Subsidiaries of CLTX Earned surplus (deficit) Additional information
Bankers Life $(5.1) (a)
Colonial Penn (513.3) (b)

(a) Bankers Life paid dividends of $30.0 million to CLTX in the first three months of 2024. Bankers Life may pay dividends without regulatory approval or prior notice for any 12-month period if such dividends are less than the greater of: (i) statutory net income for the prior year; or (ii) 10 percent of statutory capital and surplus as of the end of the preceding year. Dividends in excess of these levels require 30 days prior notice. In the event Bankers Life's earned surplus balance is zero or in a deficit position, Bankers Life may request approval from the Illinois Department of Insurance for return-of-capital distributions, the payment of which would be subject to prior approval.

(b) The deficit is primarily due to transactions which occurred several years ago, including a tax planning transaction and the fee paid to recapture a block of business previously ceded to an unaffiliated insurer.

A significant deterioration in the financial condition, earnings or cash flow of the material subsidiaries of CNO or CDOC for any reason could hinder such subsidiaries' ability to pay cash dividends or other disbursements to CNO and/or CDOC, which, in turn, could limit CNO's ability to meet debt service requirements and satisfy other financial obligations. In addition, we may choose to retain capital in our insurance subsidiaries or to contribute additional capital to our insurance subsidiaries to maintain or strengthen their surplus or fund reinsurance transactions, and these decisions could limit the amount available at our top tier insurance subsidiaries to pay dividends to the holding companies. In the first three months of 2024, CDOC made capital contributions of $24.7 million to CLTX.

At March 31, 2024, there were no amounts outstanding under our $250 million Revolving Credit Agreement and there are no scheduled repayments of our direct corporate obligations until May 2025.

Free cash flow is a measure of holding company liquidity and is calculated as: (i) dividends, management fees and surplus debenture interest payments received from our subsidiaries; plus (ii) earnings on corporate investments; less (iii) interest expense, corporate expenses and net tax payments. In the first three months of 2024, we generated $34 million of such free cash flow. The Company expects to deploy its free cash flow into investments to accelerate profitable growth, common stock dividends and share repurchases. The amount and timing of future share repurchases (if any) will be based on business and market conditions and other factors including, but not limited to, available free cash flow, the current price of our common stock and investment opportunities. In the first three months of 2024, we repurchased 1.5 million shares of common stock for $40.0 million under our securities repurchase program (including $0.8 million of repurchases settled in the second quarter of 2024). The Company had remaining repurchase authority of $481.8 million as of March 31, 2024.

In the first three months of 2024, dividends declared on common stock totaled $16.4 million ($0.15 per common share). In May 2024, the Company increased its quarterly common stock dividend to $0.16 per share from $0.15 per share.

On March 18, 2024, S&P affirmed its "BBB-" rating on our senior unsecured debt and the outlook for these ratings is stable. In S&P's view, an obligation rated "BBB" exhibits adequate protection parameters. However, adverse economic conditions or changing circumstances are more likely to lead to a weakened capacity of the obligor to meet its financial commitment on the obligation. Pluses and minuses show the relative standing within a category. S&P has a total of twenty-two possible ratings ranging from "AAA (Extremely Strong)" to "D (Payment Default)". There are nine ratings above CNO's "BBB-" rating and twelve ratings that are below its rating.

On February 15, 2024, AM Best affirmed its "bbb" rating on our issuer credit and senior unsecured debt and the outlook for these ratings is stable. In AM Best's view, a company rated "bbb" has an adequate ability to meet the terms of its obligations; however, the issuer is more susceptible to changes in economic or other conditions. Pluses and minuses show the relative standing within a category. AM Best has a total of twenty-two possible ratings ranging from "aaa (Exceptional)" to "d (In default)". There are eight ratings above CNO's "bbb" rating and thirteen ratings that are below its rating.

On November 15, 2023, Fitch upgraded our senior unsecured debt ratings to "BBB+" from "BBB". The outlook for these ratings is stable. In Fitch's view, an obligation rated "BBB" indicates that expectations of default risk are currently low. The capacity for payment of financial commitments is considered adequate but adverse business or economic conditions are more likely to impair this capacity. Pluses and minuses show the relative standing within a category. Fitch has a total of 21 possible ratings ranging from "AAA" to "D". There are eight ratings above CNO's "BBB+" rating and twelve ratings that are below its rating.

Moody's most recently reviewed its "Baa3" rating on our senior unsecured debt on May 12, 2023. The outlook for these ratings remains stable. In Moody's view, obligations rated "Baa" are subject to moderate credit risk and may possess certain speculative characteristics. A rating is supplemented with numerical modifiers "1", "2" or "3" to show the relative standing within a category. Moody's has a total of twenty-one possible ratings ranging from "Aaa" to "C". There are nine ratings above CNO's "Baa3" rating and eleven ratings that are below its rating.

We believe that the existing cash available to the holding company, the cash flows to be generated from operations and other transactions will be sufficient to allow us to meet our debt service obligations, pay corporate expenses and satisfy other financial obligations. However, our cash flow is affected by a variety of factors, many of which are outside of our control, including insurance regulatory issues, competition, financial markets and other general business conditions. We cannot provide assurance that we will possess sufficient income and liquidity to meet all of our debt service requirements and other holding company obligations.

INVESTMENTS

At March 31, 2024, the amortized cost, gross unrealized gains, gross unrealized losses, allowance for credit losses and estimated fair value of fixed maturities, available for sale, were as follows (dollars in millions):

Investment grade (a): Amortized cost Gross unrealized gains Gross unrealized losses Allowance for credit losses Estimated fair value
Corporate securities $12,557.8 $48.9 $(1,474.6) $(21.5) $11,110.6
United States Treasury securities and obligations of United States government corporations and agencies 232.8 — (18.4) — 214.4
States and political subdivisions 3,044.9 26.4 (376.3) (.5) 2,694.5
Foreign governments 94.8 .6 (12.5) (.6) 82.3
Asset-backed securities 1,436.8 3.2 (81.6) (.1) 1,358.3
Agency residential mortgage-backed securities 683.3 6.7 (2.3) — 687.7
Non-agency residential mortgage-backed securities 1,189.0 6.8 (128.6) — 1,067.2
Collateralized loan obligations 1,151.0 4.6 (10.0) — 1,145.6
Commercial mortgage-backed securities 2,296.7 1.8 (196.4) — 2,102.1
Total investment grade fixed maturities, available for sale 22,687.1 99.0 (2,300.7) (22.7) 20,462.7
Below-investment grade (a) (b):
Corporate securities 574.9 1.6 (32.0) (16.2) 528.3
States and political subdivisions 9.6 — (.6) (.1) 8.9
Asset-backed securities 109.3 .1 (13.8) — 95.6
Non-agency residential mortgage-backed securities 481.4 26.8 (15.6) — 492.6
Commercial mortgage-backed securities 88.5 — (28.5) — 60.0
Total below-investment grade fixed maturities, available for sale 1,263.7 28.5 (90.5) (16.3) 1,185.4
Total fixed maturities, available for sale $23,950.8 $127.5 $(2,391.2) $(39.0) $21,648.1

(a) Investment ratings are assigned the second lowest rating by Nationally Recognized Statistical Rating Organizations ("NRSROs") (Moody's, S&P or Fitch), or if not rated by such firms, the rating assigned by the National Association of Insurance Commissioners (the "NAIC"). NAIC designations of "1" or "2" include fixed maturities generally rated investment grade (rated "Baa3" or higher by Moody's or rated "BBB-" or higher by S&P and Fitch). NAIC designations of "3" through "6" are referred to as below-investment grade (which generally are rated "Ba1" or lower by Moody's or rated "BB+" or lower by S&P and Fitch). References to investment grade or below-investment grade throughout our consolidated financial statements are determined as described above.

(b) Certain structured securities rated below-investment grade by NRSROs may be assigned a NAIC 1 or NAIC 2 designation based on the cost basis of the security relative to estimated recoverable amounts as determined by the NAIC. Refer to the table below for a summary of our fixed maturity securities, available for sale, by NAIC designations.

The NAIC evaluates the fixed maturity investments of insurers for regulatory and capital assessment purposes and assigns securities to one of six credit quality categories called NAIC designations, which are used by insurers when preparing their annual statements based on statutory accounting principles. The NAIC designations are generally similar to the credit quality designations of the NRSROs for marketable fixed maturity securities, except for certain structured securities. However, certain structured securities rated below investment grade by the NRSROs can be assigned NAIC 1 or NAIC 2 designations depending on the cost basis of the holding relative to estimated recoverable amounts as determined by the NAIC. The following summarizes the NAIC designations and NRSRO equivalent ratings:

NAIC Designation NRSRO Equivalent Rating
1 AAA/AA/A
2 BBB
3 BB
4 B
5 CCC and lower
6 In or near default

A summary of our fixed maturity securities, available for sale, by NAIC designations (or for fixed maturity securities held by non-regulated entities, based on NRSRO ratings) as of March 31, 2024 is as follows (dollars in millions):

NAIC designation Amortized cost Estimated fair value Percentage of total estimated fair value
1 $15,421.3 $13,971.4 64.5%
2 7,807.0 7,030.1 32.5
Total NAIC 1 and 2 (investment grade) 23,228.3 21,001.5 97.0
3 535.6 484.1 2.2
4 147.7 138.2 .7
5 29.2 21.8 .1
6 10.0 2.5 —
Total NAIC 3, 4, 5 and 6 (below-investment grade) 722.5 646.6 3.0
Total $23,950.8 $21,648.1 100.0%

89

Fixed Maturity Securities, Available for Sale

The following table summarizes the carrying values and gross unrealized losses of our fixed maturity securities, available for sale, by category as of March 31, 2024 (dollars in millions):

Carrying value Percent of fixed maturities Gross unrealized losses Percent of gross unrealized losses
States and political subdivisions $2,703.4 12.5% $376.9 15.8%
Commercial mortgage-backed securities 2,162.1 10.0 224.9 9.4
Banks 1,801.8 8.3 195.2 8.2
Non-agency residential mortgage-backed securities 1,559.8 7.2 144.2 6.0
Asset-backed securities 1,453.9 6.7 95.4 4.0
Collateralized loan obligations 1,145.6 5.3 10.0 .4
Insurance 1,112.1 5.1 173.8 7.3
Utilities 1,101.9 5.1 151.1 6.3
Healthcare/pharmaceuticals 1,037.9 4.8 185.1 7.7
Brokerage 946.8 4.4 108.5 4.5
Technology 763.3 3.5 127.9 5.3
Agency residential mortgage-backed securities 687.7 3.2 2.3 .1
Food/beverage 628.8 2.9 73.9 3.1
Energy 505.5 2.3 35.0 1.5
Cable/media 433.3 2.0 71.4 3.0
Real estate/REITs 336.7 1.5 43.6 1.8
Transportation 319.3 1.5 35.7 1.5
Telecom 315.7 1.5 23.1 1.0
Capital goods 275.5 1.3 30.4 1.3
Chemicals 258.9 1.2 31.9 1.3
Other 2,098.1 9.7 250.9 10.5
Total fixed maturities, available for sale $21,648.1 100.0% $2,391.2 100.0%

Below-Investment Grade Securities

At March 31, 2024, the amortized cost of the Company's below-investment grade fixed maturity securities, available for sale, was $1,263.7 million, or 5.3 percent of the Company's fixed maturity portfolio (or $722.5 million, or 3.0 percent, of the Company's fixed maturity portfolio measured on credit quality ratings assigned by the NAIC). The estimated fair value of the below-investment grade portfolio was $1,185.4 million, or 94 percent of the amortized cost.

Below-investment grade corporate debt securities typically have different characteristics than investment grade corporate debt securities. Based on historical performance, probability of default by the borrower is significantly greater for below-investment grade corporate debt securities and in many cases severity of loss is relatively greater as such securities are generally unsecured and often subordinated to other indebtedness of the issuer. Also, issuers of below-investment grade corporate debt securities frequently have higher levels of debt relative to investment-grade issuers, hence, all other things being equal, are generally more sensitive to adverse economic conditions. The Company attempts to reduce the overall risk related to its investment in below-investment grade securities, as in all investments, through careful credit analysis, strict investment policy guidelines, and diversification by issuer and/or guarantor and by industry.

Net Realized and Unrealized Investment Losses

During the first three months of 2024, we recognized $5.9 million of realized losses on sales of $197.1 million of fixed maturity securities, available for sale, including: (i) $3.5 million related to various corporate securities; (ii) $1.1 million related to commercial mortgage-backed securities; and (iii) $1.3 million related to various other investments. Securities are generally sold at a loss following unforeseen issuer-specific events or conditions or shifts in perceived relative values. These reasons include but are not limited to: (i) changes in the investment environment; (ii) expectation that the market value could deteriorate; (iii) our desire to reduce our exposure to an asset class, an issuer or an industry; (iv) prospective or actual changes in credit quality; (v) better match certain characteristics of our investment portfolio with the corresponding characteristics of our insurance liabilities; or (vi) changes in expected portfolio cash flows.

During the first three months of 2023, we recognized $14.4 million of realized losses on sales of $288.5 million of fixed maturity securities, available for sale, including: (i) $11.1 million related to various corporate securities; (ii) $2.2 million related to commercial mortgage-backed securities; and (iii) $1.1 million related to various other investments.

The following summarizes the investments sold at a loss during the first three months of 2024 which had been

continuously in an unrealized loss position exceeding 20 percent of the amortized cost basis prior to the sale for the period

indicated (dollars in millions):

Number of issuers At date of sale Amortized cost Fair value
Less than 6 months prior to sale 1 $3.5 $2.1

Future events may occur, or additional information may become available, which may necessitate future realized losses in our portfolio. Significant losses could have a material adverse effect on our consolidated financial statements in future periods.

The following table sets forth the amortized cost and estimated fair value of those fixed maturities, available for sale, with unrealized losses at March 31, 2024, by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties. Structured securities frequently include provisions for periodic principal payments and permit periodic unscheduled payments.

(Dollars in millions)

Amortized cost Estimated fair value
Due in one year or less $274.7 $264.3
Due after one year through five years 1,961.0 1,852.8
Due after five years through ten years 1,059.0 965.6
Due after ten years 10,856.0 9,114.8
Subtotal 14,150.7 12,197.5
Structured securities 5,618.8 5,141.9
Total $19,769.5 $17,339.4

91

The following summarizes the investments in our portfolio rated below-investment grade not deemed to have credit losses which have been continuously in an unrealized loss position exceeding 20 percent of the cost basis for the period indicated as of March 31, 2024 (dollars in millions):

Number of issuers Cost basis Unrealized loss Estimated fair value
Greater than or equal to 6 months and less than 12 months 3 $7.5 $(3.2) $4.3
Greater than 12 months 5 62.9 (23.7) 39.2
Total $70.4 $(26.9) $43.5

92

The following table summarizes the gross unrealized losses of our fixed maturity securities, available for sale, by category and ratings category as of March 31, 2024 (dollars in millions):

Investment grade AAA/AA/A BBB Below-investment grade BB B+ and below Total gross unrealized losses
States and political subdivisions $369.0 $7.3 $— $.6 $376.9
Commercial mortgage-backed securities 163.0 33.4 20.8 7.7 224.9
Banks 111.7 81.0 2.5 — 195.2
Healthcare/pharmaceuticals 134.7 48.3 1.7 .4 185.1
Insurance 91.2 80.1 2.4 .2 173.9
Utilities 88.4 61.7 1.0 — 151.1
Non-agency residential mortgage-backed securities 89.2 39.4 2.3 13.3 144.2
Technology 86.5 38.5 2.5 .4 127.9
Brokerage 55.6 51.9 .8 .2 108.5
Asset-backed securities 35.8 45.8 13.5 .3 95.4
Food/beverage 26.0 46.8 .9 .2 73.9
Cable/media 9.8 57.5 1.3 2.8 71.4
Real estate/REITs 27.6 15.9 .1 — 43.6
Education 39.9 3.1 — — 43.0
Transportation 17.0 18.6 — .1 35.7
Consumer products 21.3 10.6 2.8 .6 35.3
Energy 8.1 26.8 .1 — 35.0
Chemicals 2.6 28.9 .4 — 31.9
Capital goods 16.9 11.5 1.9 .1 30.4
Retail 18.6 4.4 5.5 .5 29.0
Aerospace/defense 6.0 17.5 — .2 23.7
Telecom .1 23.0 — — 23.1
Autos 3.8 14.8 .2 .2 19.0
Building materials 5.1 13.1 .4 .1 18.7
United States Treasury securities and obligations of United States government corporations and agencies 18.4 — — — 18.4
Metals and mining 4.8 8.1 .4 — 13.3
Foreign governments 5.8 6.7 — — 12.5
Collateralized loan obligations 9.5 .5 — — 10.0
Paper .6 9.0 — — 9.6
Entertainment/hotels 5.6 3.7 .1 — 9.4
Agency residential mortgage-backed securities 2.3 — — — 2.3
Business services — .9 .3 .3 1.5
Other 16.6 .4 .3 .1 17.4
Total fixed maturities, available for sale $1,491.5 $809.2 $62.2 $28.3 $2,391.2

Our investment strategy is to maximize, over a sustained period and within acceptable parameters of quality and risk, investment income and total investment return through active strategic asset allocation and investment management.

Accordingly, we may sell securities at a gain or a loss to enhance the projected total return of the portfolio as market opportunities change, to reflect changing perceptions of risk, or to better match certain characteristics of our investment portfolio with the corresponding characteristics of our insurance liabilities.

Structured Securities

At March 31, 2024, fixed maturity investments included structured securities with an estimated fair value of $7.0 billion (or 32.4 percent of all fixed maturity securities). The yield characteristics of structured securities generally differ in some respects from those of traditional corporate fixed-income securities or government securities. For example, interest and principal payments on structured securities may occur more frequently, often monthly. In many instances, we are subject to variability in the amount and timing of principal and interest payments. For example, in many cases, partial prepayments may occur at the option of the issuer and prepayment rates are influenced by a number of factors that cannot be predicted with certainty, including: the relative sensitivity of prepayments on the underlying assets backing the security to changes in interest rates and asset values; the availability of alternative financing; a variety of economic, geographic and other factors; the timing, pace and proceeds of liquidations of defaulted collateral; and various security-specific structural considerations (for example, the repayment priority of a given security in a securitization structure). In addition, the total amount of payments for non-agency structured securities may be affected by changes to cumulative default rates or loss severities of the related collateral.

The amortized cost and estimated fair value of structured securities at March 31, 2024, summarized by type of security, were as follows (dollars in millions):

Type Amortized cost Estimated fair value Amount Percent of fixed maturities
Asset-backed securities $1,546.1 $1,453.9 6.7%
Agency residential mortgage-backed securities 683.3 687.7 3.2
Non-agency residential mortgage-backed securities 1,670.4 1,559.8 7.2
Collateralized loan obligations 1,151.0 1,145.6 5.3
Commercial mortgage-backed securities 2,385.2 2,162.1 10.0
Total structured securities $7,436.0 $7,009.1 32.4%

Residential mortgage-backed securities ("RMBS") include transactions collateralized by agency-guaranteed and non-agency mortgage obligations. Non-agency RMBS investments are primarily categorized by underlying borrower credit quality: Prime, Alt-A, Non-Qualified Mortgage ("Non-QM"), and Subprime. Prime borrowers typically default with the lowest frequency, Alt-A and Non-QM default at higher rates, and Subprime borrowers default with the highest frequency. In addition to borrower credit categories, RMBS investments include Re-Performing Loan ("RPL") and Credit Risk Transfer ("CRT") transactions. RPL transactions include borrowers with prior difficulty meeting the original mortgage terms and were subsequently modified, resulting in a sustainable payback arrangement. CRT securities are collateralized by Government-Sponsored Enterprise ("GSE") conforming mortgages and Prime borrowers, but without an agency guarantee against default losses.

Commercial mortgage-backed securities ("CMBS") are secured by commercial real estate mortgages, generally income producing properties that are managed for profit. Property types include, but are not limited to, multi-family dwellings including apartments, retail centers, hotels, restaurants, hospitals, nursing homes, warehouses, and office buildings. While most CMBS have call protection features whereby underlying borrowers may not prepay their mortgages for stated periods of time without incurring prepayment penalties, recoveries on defaulted collateral may result in involuntary prepayments.

INVESTMENTS IN VARIABLE INTEREST ENTITIES

The following table provides supplemental information about the revenues and expenses of the VIEs which have been consolidated in accordance with authoritative guidance, after giving effect to the elimination of our investment in the VIEs and investment management fees earned by a subsidiary of the Company (dollars in millions):

Revenues: Three months ended March 31, 2024 2023
Net investment income – policyholder and other special-purpose portfolios $14.0 $22.4
Fee revenue and other income .9 1.3
Total revenues 14.9 23.7
Expenses:
Interest expense 11.9 17.3
Other operating expenses .5 .5
Total expenses 12.4 17.8
Income before net investment losses and income taxes 2.5 5.9
Net investment losses (3.6) (.6)
Income (loss) before income taxes $(1.1) $5.3

95

Supplemental Information on Investments Held by VIEs

The following table summarizes the carrying values and gross unrealized losses of the investments held by the VIEs by category as of March 31, 2024 (dollars in millions):

Carrying value Percent of fixed maturities Gross unrealized losses Percent of gross unrealized losses
Cable/media $71.4 13.4% $3.2 28.5%
Technology 68.9 12.9 1.5 13.5
Healthcare/pharmaceuticals 62.6 11.7 1.8 16.3
Brokerage 36.6 6.9 .1 .4
Food/beverage 35.9 6.7 1.5 13.3
Chemicals 27.8 5.2 .1 1.1
Building materials 27.0 5.1 .1 1.1
Capital goods 24.7 4.6 .4 3.4
Transportation 23.5 4.4 .1 .6
Paper 23.1 4.3 .1 .5
Utilities 21.6 4.0 .2 2.1
Autos 19.5 3.7 .1 .7
Consumer products 18.8 3.5 .4 3.9
Business services 16.8 3.2 .4 3.6
Insurance 15.5 2.9 — .2
Metals and mining 5.1 1.0 — —
Other 34.6 6.5 1.2 10.8
Total $533.4 100.0% $11.2 100.0%

The following table sets forth the amortized cost and estimated fair value of those investments held by the VIEs with unrealized losses at March 31, 2024, by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.

(Dollars in millions)

Amortized cost Estimated fair value
Due in one year or less $12.2 $11.7
Due after one year through five years 290.8 276.2
Due after five years through ten years 5.4 5.0
Total $308.4 $292.9

96

The following summarizes the investments held by the VIEs sold at a loss during the first three months of 2024 which had been continuously in an unrealized loss position exceeding 20 percent of the amortized cost basis prior to the sale for the period indicated (dollars in millions):

Number of issuers At date of sale Amortized cost Fair value
Less than 6 months prior to sale 5 $4.4 $3.5
Greater than or equal to 6 months and less than 12 months prior to sale 2 2.8 1.8
Greater than 12 months prior to sale 5 6.9 3.5
$14.1 $8.8

There were no investments held by the VIEs rated below-investment grade not deemed to have credit losses which had been continuously in an unrealized loss position exceeding 20 percent of the cost basis as of March 31, 2024.

NEW ACCOUNTING STANDARDS

See "Recently Issued Accounting Standards" in the notes to consolidated financial statements for a discussion of recently issued accounting standards.

Market risk

As filed, 351 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our market risks, and the ways we manage them, are summarized in "Management's Discussion and Analysis of Financial Condition and Results of Operations", included in our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes in the first three months of 2024 to such risks or our management of such risks.

Controls and procedures

As filed, 1,432 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures. CNO's management, under the supervision and with the participation of the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of CNO's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, (the "Exchange Act")). Based on its evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2024, CNO's disclosure controls and procedures were effective to ensure that information required to be disclosed by CNO in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes to Internal Control Over Financial Reporting. There were no changes in the Company's internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the three months ended March 31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 456 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

CNO and its businesses are subject to a number of risks including general business and financial risk. Any or all of such risks could have a material adverse effect on the business, financial condition or results of operations of CNO. Refer to "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, for further discussion of such risk factors. There have been no material changes from such previously disclosed risk factors.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2024-01-01 to 2024-03-31$1.16bnus-gaap:Revenues
Operating income3 months2024-01-01 to 2024-03-31$74.8mus-gaap:OperatingIncomeLoss
Interest expense3 months2024-01-01 to 2024-03-31$60.2mus-gaap:InterestExpense
Income tax3 months2024-01-01 to 2024-03-31$33.9mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2024-01-01 to 2024-03-31$112.3mus-gaap:NetIncomeLoss
Diluted EPS3 months2024-01-01 to 2024-03-31$1.01us-gaap:EarningsPerShareDiluted
Basic EPS3 months2024-01-01 to 2024-03-31$1.03us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2024-01-01 to 2024-03-31110,845,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2024-01-01 to 2024-03-31$94.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Dividends paid3 months2024-01-01 to 2024-03-31$17.3mus-gaap:PaymentsOfDividends
Share repurchases3 months2024-01-01 to 2024-03-31$58.8mus-gaap:PaymentsForRepurchaseOfCommonStock
Total assetsAt period end2024-03-31$34.94bnus-gaap:Assets
Total liabilitiesAt period end2024-03-31$32.57bnus-gaap:Liabilities
Shareholders' equityAt period end2024-03-31$2.37bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001224608-24-000041. Last ingested by Listed: Nov 14, 2026, 19:45 ET. Listed shows no prices and gives no investment advice.